Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRCX014 + temozolomide
- Development stage
- Unknown
- Lead developer
- Leaf Vertical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BRCX014 + temozolomide is an investigational combination therapy being developed by Leaf Vertical Inc. for the treatment of glioblastoma (GBM). BRCX014 is a proprietary cannabinoid formulation containing cannabidiol (CBD). Temozolomide is a standard-of-care DNA alkylating chemotherapy agent. The combination is designed to leverage the potential anti-tumor effects of cannabinoids—such as modulating cell signaling pathways, inhibiting angiogenesis, and inducing apoptosis—to enhance the efficacy of temozolomide and potentially overcome chemotherapy resistance in patients with glioblastoma, particularly those with non-methylated MGMT gene status. The therapy is currently being evaluated in a Phase I clinical trial (NCT03687034) to assess safety and pharmacokinetics when administered alongside standard-of-care chemoradiation.
- Other names
- cannabidiol + temozolomide
02
Targets
DNA
Beyond the preview
Go deeper on BRCX014 + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRCX014 + temozolomide.